Johnson & Johnson’s (NYSE:JNJ) Outperform was reiterated by analysts at Cowen in a note to investors on Monday.
Merck & Co. (NYSE:MRK) reported Monday that new data from Phase III evaluations of Victrelis (boceprevir) 200 mg capsules, the firm’s oral hepatitis C virus NS3/4A protease inhibitor, will be presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases in Boston, November 9th to the 13th.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Pfizer, Inc. (NYSE:PFE) and Bristol Myers Squibb Co. (NYSE:BMY) might not hear a decision as to whether their experimental blood thinner Eliquis is approved by the FDA until March 2013. Pfizer shares were still up moderately in late afternoon trading.
UnitedHealth Group’s (NYSE:UNH) UnitedHealthcare released its 2013 Medicare portfolio on Monday, which includes a new low-premium Part D plan along with a preferred pharmacy network that will provide greater cost-savings and value to Medicare consumers. Many of UnitedHealthcare’s medical and prescription drug plans carry the AARP brand and were designed to help meet the varying requirements of the 49 million current beneficiaries as well as some early baby boomers who began aging into Medicare in 2011. Medicare beneficiaries may make changes to their health coverage during the Open Enrollment Period which begins Oct. 15th.
Don’t Miss: What’s Next in Pfizer’s Pipeline?